コンテンツへスキップ
Merck

Depot fluphenazine: risk/benefit ratio.

The Journal of clinical psychiatry (1984-05-01)
W M Glazer
要旨

The risks and benefits associated with depot fluphenazine are reassessed by a review and critique of the literature, with an emphasis on controlled studies comparing depot to oral preparations. Specific gaps in our knowledge are noted and recommendations are made for future research.

材料
製品番号
ブランド
製品内容

Fluphenazine enantate, European Pharmacopoeia (EP) Reference Standard